Completion of patient dosing in a Phase III physician-initiated clinical trial evaluating the efficacy of RS5614 in combination with a tyrosine kinase inhibitor (TKI) for chronic-phase chronic myeloid leukemia (CML)
Renascience Inc., Tohoku University, Tokai University, Akita University and 12 other domestic universities and medical institutions
Phase III physician-initiated clinical trial of the PAI-1 inhibitor RS5614 in combination with a tyrosine kinase inhibitor (TKI) for chronic-phase chronic myeloid leukemia (CML) (12 domestic universities and medical institutions)
Fiscal year ending March 2027 (the period to which the impact on results from this matter applies)
This matter is not expected to have any particular impact on results for the fiscal year ending March 2027 at this time.
The results of the trial evaluation and data analysis will be compiled into the clinical trial report.
| Item | Details |
|---|---|
| Event name | Completion of patient dosing in a Phase III physician-initiated clinical trial evaluating the efficacy of RS5614 in combination with a tyrosine kinase inhibitor (TKI) for chronic-phase chronic myeloid leukemia (CML) |
| Date of occurrence | 29 September 2026 (the date dosing was completed for all 57 enrolled patients) |
| Subject Entity | Renascience Inc., Tohoku University, Tokai University, Akita University and 12 other domestic universities and medical institutions |
| Target Locations / Products | Phase III physician-initiated clinical trial of the PAI-1 inhibitor RS5614 in combination with a tyrosine kinase inhibitor (TKI) for chronic-phase chronic myeloid leukemia (CML) (12 domestic universities and medical institutions) |
| Accounting period in which recognized | Fiscal year ending March 2027 (the period to which the impact on results from this matter applies) |
| Impact on Earnings Forecast | This matter is not expected to have any particular impact on results for the fiscal year ending March 2027 at this time. |
| Outlook | The results of the trial evaluation and data analysis will be compiled into the clinical trial report. |
| Planned follow-up disclosure | The results of the trial evaluation and data analysis will be compiled into the clinical trial report. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No specific reason for completion of dosing was disclosed. The company stated that patient enrolment had been completed and that the trial was progressing smoothly as scheduled.